By Matthew Stenger  / Tuesday, September 3, 2013 10:29 AM

First-Line Brivanib Not Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma

The investigational drug brivanib is a dual inhibitor of VEGF and fibroblast growth factor signaling, both implicated in hepatocellular carcinoma. In a noninferiority trial (BRISK-FL) reported in Journal of Clinical Oncology, Philip J. Johnson, MD, of the Institute of Translational Medicine,...